ATE297190T1 - Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln - Google Patents

Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln

Info

Publication number
ATE297190T1
ATE297190T1 AT00907228T AT00907228T ATE297190T1 AT E297190 T1 ATE297190 T1 AT E297190T1 AT 00907228 T AT00907228 T AT 00907228T AT 00907228 T AT00907228 T AT 00907228T AT E297190 T1 ATE297190 T1 AT E297190T1
Authority
AT
Austria
Prior art keywords
microparticles
emulsifying agent
oil
microemulsions
emulsion
Prior art date
Application number
AT00907228T
Other languages
German (de)
English (en)
Inventor
Derek O'hagan
Gary S Ott
John Donnelly
Jina Kazzaz
Mildred Ugozzoli
Manmohan Singh
John Barackman
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27382688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297190(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE297190T1 publication Critical patent/ATE297190T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Colloid Chemistry (AREA)
AT00907228T 1999-02-26 2000-02-09 Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln ATE297190T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12185899P 1999-02-26 1999-02-26
US14639199P 1999-07-29 1999-07-29
US16199799P 1999-10-28 1999-10-28
PCT/US2000/003331 WO2000050006A2 (en) 1999-02-26 2000-02-09 Microemulsions with adsorbed macromoelecules and microparticles

Publications (1)

Publication Number Publication Date
ATE297190T1 true ATE297190T1 (de) 2005-06-15

Family

ID=27382688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907228T ATE297190T1 (de) 1999-02-26 2000-02-09 Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln

Country Status (9)

Country Link
US (4) US8206749B1 (enExample)
EP (3) EP1574210B1 (enExample)
JP (4) JP2002537102A (enExample)
AT (1) ATE297190T1 (enExample)
AU (1) AU2875700A (enExample)
CA (2) CA2363141C (enExample)
DE (1) DE60020677T2 (enExample)
ES (2) ES2242604T3 (enExample)
WO (1) WO2000050006A2 (enExample)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
DE60125795T2 (de) 2000-09-28 2007-10-18 Novartis Vaccines and Diagnostics, Inc., Emeryville Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US6552004B1 (en) * 2000-10-30 2003-04-22 Universite De Montreal Delivery system for entrapping charged macromolecules and a method for preparing same
US20030049266A1 (en) 2000-12-27 2003-03-13 Fearon Karen L. Immunomodulatory polynucleotides and methods of using the same
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
ES2335979T3 (es) * 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
CA2471968C (en) * 2001-10-06 2013-07-23 Merial Limited Immunostimulatory nucleic acids and use thereof
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
JP4726485B2 (ja) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 細菌細胞壁骨格成分製剤
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP2006520746A (ja) 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AP2195A (en) 2004-01-23 2011-01-10 Eden Research Plc Methods of killing nematodes comprising the application of a terpene component.
WO2005113128A1 (en) 2004-05-20 2005-12-01 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
KR20160064249A (ko) 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
JP2008535918A (ja) * 2005-04-11 2008-09-04 ナノバイオ コーポレーション 感染性の症状を処置するための四級アンモニウムハライド
KR101359953B1 (ko) 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2792398T3 (es) * 2005-11-04 2020-11-11 Seqirus Uk Ltd Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
PT1951300E (pt) * 2005-11-04 2011-09-05 Novartis Vaccines & Diagnostic Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
DE202006021242U1 (de) * 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
EP2530086B1 (en) 2006-06-12 2019-03-20 Kuros Biosciences AG Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2008241413A1 (en) * 2007-04-18 2008-10-30 The Regents Of The University Of California Protein-modified nano-droplets, compositions and methods of production
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
CA2719252C (en) * 2008-04-01 2016-01-19 Innate Therapeutics Limited Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2280690A2 (en) * 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
WO2009132343A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating onchomycosis
AU2009240389A1 (en) 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
EP3725328A3 (en) 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
ES2566646T3 (es) * 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
GB0913442D0 (en) * 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
SG10201501611QA (en) * 2009-12-03 2015-04-29 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions
BR112012013425A2 (pt) 2009-12-03 2020-11-03 Novartis Ag filtração hidrofílica durante a fabricação de adjuvantes de vacinas
AU2013202706B2 (en) * 2009-12-03 2016-02-11 Seqirus UK Limited Circulation of components during microfluidization and/or homogenization emulsions
WO2012006380A2 (en) * 2010-07-06 2012-01-12 Novartis Ag Cationic oil-in-water emulsions
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
PL2624873T3 (pl) 2010-10-06 2020-12-14 President And Fellows Of Harvard College Nadające się do wstrzykiwania hydrożele tworzące pory do terapii komórkowych opartych na materiałach
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6062426B2 (ja) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インサイチュー抗原生成癌ワクチン
BR112014000235A8 (pt) 2011-07-06 2018-03-06 Novartis Ag emulsões de óleo em água catiônicas
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
EP2747779A4 (en) * 2011-08-22 2015-04-08 Nanobio Corp HERPES SIMPLEX VIRUS VACCINE NANOEMULSION
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
BR112014023068B1 (pt) * 2012-03-23 2022-03-03 Amicrobe, Inc Composição aquosa para prevenir, inibir ou tratar infecção e respectivo uso
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2838515T3 (pl) 2012-04-16 2020-06-29 President And Fellows Of Harvard College Kompozycje mezoporowatego krzemu do modulowania odpowiedzi odpornościowych
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
US20150250872A1 (en) 2012-09-21 2015-09-10 Frank Bedu-Addo Vaccine compositions and methods of use
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015042369A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
EP2851066A1 (en) * 2013-09-23 2015-03-25 LTS LOHMANN Therapie-Systeme AG Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3204039B1 (en) * 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
CN114699518B (zh) 2015-01-16 2024-07-02 硕腾服务有限责任公司 口蹄疫疫苗
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
WO2017004250A1 (en) 2015-06-29 2017-01-05 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Systems and methods for continuous flow digital droplet polymerase chain reaction bioanalysis
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
SMT202200178T1 (it) 2015-09-17 2022-05-12 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti terapeutici
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US11643441B1 (en) 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
EP3468530A4 (en) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. NON-COMEDOGEN FORMULA FOR HAIR AND SCALP CARE AND METHOD FOR USE
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
KR102638898B1 (ko) 2016-08-02 2024-02-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 면역 반응을 조정하기 위한 생체재료
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
EP3544737B1 (en) 2016-11-28 2025-04-23 Arizona Board of Regents on behalf of Arizona State University Methods related to continuous flow droplet reaction
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
LT3596041T (lt) 2017-03-15 2023-01-25 Modernatx, Inc. Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3606543A4 (en) 2017-04-06 2020-12-16 Amicrobe, Inc. COMPOSITIONS AND USES OF LOCALLY APPLIED ANTIMICROBIALS WITH IMPROVED PERFORMANCE AND SAFETY
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
WO2019169370A1 (en) * 2018-03-02 2019-09-06 University Of The Sciences Polymer compositions for storage and release of polypeptides
CN112236218B (zh) 2018-04-02 2022-04-26 滴管公司 用于连续流乳液处理的系统和方法
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
WO2020246584A1 (ja) * 2019-06-06 2020-12-10 デンカ株式会社 ペプチド核酸を基盤としたアジュバント
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
JP2023518976A (ja) 2020-03-23 2023-05-09 エイチディーティー バイオ コーポレーション Ｒｎａを送達するための組成物および方法
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送系统及其制备方法和应用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
KR20240111819A (ko) 2021-09-22 2024-07-17 에이치디티 바이오 코포레이션 암 치료 조성물 및 이들의 용도
WO2023048758A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
KR20240099177A (ko) 2021-09-22 2024-06-28 에이치디티 바이오 코포레이션 SARS-CoV-2 RNA 백신 조성물 및 사용 방법

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1565298A (en) 1925-12-15 Stop check announcing device for adding machines
CA583561A (en) 1959-09-22 H. Edgerton William Therapeutically valuable esters and methods for obtaining the same
US1573698A (en) 1922-06-21 1926-02-16 Union Carbide & Carbon Res Lab Denatured alcohol
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
FR1317586A (enExample) 1961-03-17 1963-05-08
NL280826A (enExample) 1962-07-11
BE755269A (fr) 1969-08-25 1971-02-01 Westinghouse Electric Corp Systeme de regulation d'epaisseur du produit lamine sortant d'un laminoir
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
EP0175787B1 (en) 1984-04-06 1995-02-15 Chiron Corporation RECOMBINANT HERPES SIMPLEX gB-gD VACCINE
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4826957A (en) 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
DK341386D0 (da) 1986-07-18 1986-07-18 Voetman Karin Glassau Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader
WO1988002634A1 (en) 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
ZA888209B (en) 1987-11-03 1990-07-25 Syntex Inc Vaccine adjuvant
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CH679207A5 (enExample) 1989-07-28 1992-01-15 Debiopharm Sa
AU654824B2 (en) * 1990-06-29 1994-11-24 Chiron Corporation Vaccine compositions containing liposomes
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5814516A (en) 1995-10-13 1998-09-29 Lockheed Martin Energy Systems, Inc. Surface enhanced Raman gene probe and methods thereof
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US5821060A (en) 1996-08-02 1998-10-13 Atom Sciences, Inc. DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA
WO1998015648A1 (en) 1996-10-04 1998-04-16 Dako A/S Novel probes for the detection of mycobacteria
DE19640974A1 (de) 1996-10-04 1998-04-16 Bayer Ag Bausteine für DNA/PNA-Cooligomere
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
AU739375B2 (en) 1996-11-05 2001-10-11 Clinical Micro Sensors, Inc. Electrodes linked via conductive oligomers to nucleic acids
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
EP0991403B1 (en) * 1997-01-30 2003-04-02 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
KR19980067138A (ko) * 1997-01-31 1998-10-15 박원훈 유전자 또는 생물학적 활성 약물을 세포내로 효과적으로 전달하는 지방 유제 및 그것의 제조방법
JPH10231290A (ja) 1997-02-08 1998-09-02 Boehringer Mannheim Gmbh 核酸結合化合物の調製方法
US5962230A (en) 1997-02-13 1999-10-05 The University Of Connecticut Diagnosis and treatment of glaucoma
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
DE19712530A1 (de) 1997-03-25 1998-10-01 Boehringer Mannheim Gmbh Neue Monomerbausteine zur Markierung von peptidischen Nukleinsäuren
WO1998042876A1 (en) 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
AU8298298A (en) * 1997-07-08 1999-02-08 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
SE9702776D0 (sv) * 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
CA2314934C (en) 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US6045816A (en) * 1998-06-17 2000-04-04 Isp Investments Inc. Water-based microemulsion of a pyrethroid
ATE321535T1 (de) 1998-07-29 2006-04-15 Chiron Corp Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
EP1574210B1 (en) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
KR100701569B1 (ko) 2006-07-10 2007-03-29 주식회사 경동나비엔 응축방지를 위한 저장식 보일러의 열교환기 구조
EP2019117A1 (en) 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
US8804125B2 (en) 2010-03-12 2014-08-12 Konica Minolta, Inc. Detection method for intermolecular interaction and detection device thereof
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung
CN104683216B (zh) 2013-11-29 2019-04-12 腾讯科技（深圳）有限公司 客服信息的转发方法及装置、客服系统
JP6287387B2 (ja) 2014-03-12 2018-03-07 株式会社リコー 液滴吐出装置の液体粘度検出方法、液滴吐出装置の制御方法、液滴吐出装置、及び液滴吐出装置の液体粘度を検出する回路
FR3030069B1 (fr) 2014-12-16 2020-03-20 Zrc Geneve Sa Montre a lunette tournante
KR102354328B1 (ko) 2015-09-22 2022-01-21 삼성전자주식회사 영상 표시 장치 및 그 동작 방법
US9680022B1 (en) 2016-07-12 2017-06-13 United Microelectronics Corp. Semiconductor device having silicon-germanium layer on fin and method for manufacturing the same
JP2020112507A (ja) 2019-01-16 2020-07-27 日本電信電話株式会社 案内文生成装置、案内システム、案内文生成方法及びプログラム

Also Published As

Publication number Publication date
JP6073053B2 (ja) 2017-02-01
EP1574210A3 (en) 2007-02-21
US8771747B2 (en) 2014-07-08
JP2014169323A (ja) 2014-09-18
DE60020677T2 (de) 2006-05-04
CA2689696A1 (en) 2000-08-31
CA2363141C (en) 2010-04-06
EP1156781B1 (en) 2005-06-08
EP1156781A2 (en) 2001-11-28
US8309139B2 (en) 2012-11-13
EP1574210B1 (en) 2016-04-06
US20070116709A1 (en) 2007-05-24
US20130195898A1 (en) 2013-08-01
JP2012017344A (ja) 2012-01-26
WO2000050006A2 (en) 2000-08-31
EP1574210A2 (en) 2005-09-14
CA2363141A1 (en) 2000-08-31
US8206749B1 (en) 2012-06-26
CA2689696C (en) 2013-08-06
US20130195923A1 (en) 2013-08-01
US8734832B2 (en) 2014-05-27
WO2000050006A3 (en) 2001-01-18
ES2242604T3 (es) 2005-11-16
JP2016172767A (ja) 2016-09-29
JP2002537102A (ja) 2002-11-05
ES2579783T3 (es) 2016-08-16
EP2286792A1 (en) 2011-02-23
AU2875700A (en) 2000-09-14
DE60020677D1 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
DE60020677D1 (de) Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
PT1322287E (pt) Microparticulas para a administracao de acidos nucleicos heterologos
IL142231A0 (en) Mutant cholera holotoxin as an adjuvant
WO2007006939A3 (fr) Emulsion immuno-adjuvante thermoreversible
DE69939706D1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
MY133780A (en) Vaccine composition
DE69935598D1 (de) Impfstoff enthaltend ein iscom, bestehend aus sterol und saponin und frei von zusätzlichen detergenzien
WO2004030608A3 (en) Nanoemulsion vaccines
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
EP1741782A3 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
DE69930642D1 (de) Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
LU91485I2 (fr) Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2001068129A3 (de) Adjuvans für vakzinen
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2003051288A3 (en) Mycobacterial vaccine
ATE310798T1 (de) Weichspülmittel
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
WO2000069458A3 (en) Adjuvant combinations for immunization composition and vaccines
HK1075842A (en) Nanoemulsion vaccines
EP1721618A3 (en) Proteosome influenza vaccine composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156781

Country of ref document: EP